MissionIR Articles
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin
Cybin (NEO: CYBN) is a mushroom life science company focused on the pharmaceutical development of psychedelic products. Cybin’s subsidiary Serenity Life Sciences is engaged in the research and development of psilocybin-based medications. Widely referred to…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD
Cybin (NEO: CYBN), a mushroom life science company, is at the forefront of new treatments targeting major depressive disorder (“MDD”). The company is working to become the first to bring a psilocybin drug to market…
-
Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics
CYBN partners with pioneer company focused on exploring, quantifying the human mind Innovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disorders Innovative technology opens new frontier in…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Announces API Synthesis of Multiple Tryptamine Derivatives
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc., a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing Nov.…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Strategic Partnership with Kernel
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel (“Kernel”) to leverage its innovative…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Releases Report on Patent Filings, Therapeutics Program Development
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, has provided an update on its patent filings. The company has eight filings, all tied to Cybin’s novel therapeutics, delivery mechanisms and treatment…
-
Cybin Inc. (NEO: CYBN) R&D Sees Hope in Growing Acceptance of Psilocybin
U.S. taking actionable steps toward acceptance of psilocybin States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority More psilocybin research being done focused on health, well-being of Americans facing a…
-
Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy
Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD Newly discoverable data from psychedelic…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Q1 Results for Clarmin Explorations
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, on Tuesday announced the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended Oct. 31, 2020.…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) on Track to Leverage Psychedelics to Target Depression
Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study…
-
Cybin Inc. (NEO: CYBN) on Right Path; Johns Hopkins Study Shows Psilocybin Positive Impact on Major Depression
Study published in “JAMA Psychiatry” reveals significant benefits of psilocybin for patients with major depression Most participants reported improvements; half experienced remission after only four weeks As an early entrant in the field, Cybin looks…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Joins Forces with Adelia Therapeutics to Potentially Address Treatment Gaps Beyond Major Depressive Disorder
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, today announced the close of its acquisition of 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million).…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Agreement to Acquire Adelia Therapeutics
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, recently announced its entry into a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned as Early Entrant in Rapidly Growing Field of Psychedelics
UC Berkeley and other prominent academic institutions, including Johns Hopkins University in Maryland and Imperial College in London, are accelerating scientific research of psilocybin by launching a new center focusing on the compound (https://ibn.fm/VdvfN). Cybin…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) CEO Talks Company’s Psychedelic Research, Plans on Live Trading Show
Cybin (NEO: CYBN) CEO Doug Drysdale was featured on a recent episode of TraderTV Live. Broadcast live from the DTTW trading floor, TraderTV Live is the first and only professional trading show on YouTube Live.…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Goes Public on Canada’s Next-Gen Stock Exchange
Cybin (NEO: CYBN), a leading Toronto-based biotech and life sciences company focused on psychedelic pharmaceutical therapies, today made its debut on the global public markets and is now trading on the NEO Exchange under the…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial